Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they legalize marijuana these guys will shine.. and get things done IMO .. probably just trying to save $$ right now.. w/merida on board does anyone really think they would be enabled to not get the paperwork in.. this story is far from over..
...that's ok..;)
I h-ub employs and eats pumpkin pie.. that's why no effect on ur part.. IMO
$RLFTF Aviptadil (RLF-100) The Synthetic VIP Compound: Direct Inhibition Of SAR...
For quote Google SWX: RLF
0.54 CHF -0.0100 (1.82%)
Sep 2, 12:12 PM
GP = Employee ;)
Convalescent plasma not recommended to treat COVID-19, panel says http://a.msn.com/05/en-us/BB18BJ1P?ocid=st
Convalescent plasma not recommended to treat COVID-19, panel says http://a.msn.com/05/en-us/BB18BJ1P?ocid=st
If I overexert myself, I get a burning, acidic feeling in my lungs, and breathing becomes difficult. A dry cough, along with heart palpitations, come and go. Every muscle and joint aches. If I stand up too quickly, the room gets dark and I nearly pass out.
‘I fear that I will never be the same again’: Here’s what it’s really like to be a COVID long-hauler
Ed Hornick·Senior Editor
September 1, 2020,
https://www.yahoo.com/lifestyle/i-fear-that-i-will-never-be-the-same-again-heres-what-its-really-like-to-be-a-covid-longhauler-185358665.html
If I overexert myself, I get a burning, acidic feeling in my lungs, and breathing becomes difficult. A dry cough, along with heart palpitations, come and go. Every muscle and joint aches. If I stand up too quickly, the room gets dark and I nearly pass out.
‘I fear that I will never be the same again’: Here’s what it’s really like to be a COVID long-hauler
Ed Hornick·Senior Editor
September 1, 2020,
https://www.yahoo.com/lifestyle/i-fear-that-i-will-never-be-the-same-again-heres-what-its-really-like-to-be-a-covid-longhauler-185358665.html
He posts on many boards daily.. just a promotion for his site..
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
Update: 9/1 AM
No X-rays today. Vent in APRV mode and currently set at 50%. ECMO is still 100%. Labs are all within normal range. Mean blood pressure is a little lower than what they would like it to be but just monitoring for now. Still retaining quite a bit of fluid so exploring various options to help reduce fluid balance.
Keep the prayers coming!
The vote will come during the September work period.
House set to vote on marijuana legalization https://politi.co/3b5BEim via @politico
Whole lotta people are going to be wanting RLF-100 from the looks of this article.. White House coronavirus task force shares dire report
https://www.mercurynews.com/2020/08/31/white-house-coronavirus-task-force-shares-dire-report/ via @mercnews
..every effort being made now will make RLF-100 look better later (soon)
Thanks ..over-breathing.. sounds good ..
Tony Searcy
1h ·
Update: 8/31 PM
X-rays from earlier today still showed pneumonia being present but also showed improved aeration. Vent is still in APRV mode with a setting of 50%. ECMO is still 100%. Backed off paralytics for a few hours today which is reason for ABG to not look as good. Tommy was over-breathing the machine which told them he was still mentally “there”. Nurse said it was a very good sign. Labs and other vitals looking good and holding their own.
SWX: RLF
0.53 CHF -0.032 (5.71%)
Sep 1, 9:22 AM
Update: 8/31 PM
X-rays from earlier today still showed pneumonia present but also showed some improved aeration. Vent is still in APRV mode with a setting of 50%. ECMO is still 100%. Labs and other vitals looking good and holding their own.
Trump mentioned therapeutics on the Ingraham angle interview last night.. and He separated (Therapeutics) from Plasma.. etc.. we have a few coming out he said.. along with I like them better (or they're more important .. when people get sick we can help them get better.. (paraphrased) .. the vaccine thing was reduced as a 1/3 thing ..tool to use.. kind'a downplayed it as something to go along with herd immunity.. IMO .. maybe he meant something different..
$RLFTF So far we are moving through safely with patients and we're seeing long term moves being made on the financial end. I'm guessing we're being handled by big time business entities and things are falling into place quickly for a reason. IMO
Kids back at school/online.. hearing lots of trouble at trading sites.. mmh
Kids back at school today.. ? and online..
..seeing posts ..people are saying they're having trouble with trading sites.. ??
TD Ameritrade has systems glitch.
A lot of people complaining about online brokerages today. From TD to Robin etc. Might be a reason for subdued activity.
YEP I'M HAVING PROBLEMS WITH TD ALSO
$RVVTF Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
https://www.globenewswire.com/news-release/2020/07/31/2071110/0/en/Revive-Therapeutics-Announces-U-S-FDA-Approval-of-Confirmatory-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html
$RLFTF Study has been updated:
deletion of Thomas Jefferson Hospital & Rambam Israel
5. Secondary outcome measures changed from 5 days + 30 days followup to 14 days without respiratory failure
https://clinicaltrials.gov/ct2/history/NCT04311697?A=13&B=14&C=merged#StudyPageTop
--------
Locations removed;
Criteria changed.
https://clinicaltrials.gov/ct2/show/NCT04311697
SWX: RLF
0.59 CHF +0.086 (16.93%)
Aug 31, 2:13
--
0.60 CHF +0.088 (17.32%)
Aug 31, 2:14
Re-infected With COVID-19: Two Different Viral Strains Of SARS-CoV-2 Infecting 4 Months Apart!
•Premiered 12 hours ago
WhiteBoard style discussion on the potential for COVID-19 re-infection. In this video we will discuss a case study in pre-print that found a single individual that had been infected with two different viral strains of SARS-CoV-2 almost 5 months apart.
He was first infected in March and whole genome sequencing was performed on the SARS-CoV-2 viral strain that had infected him.
He tested negative twice since then. In August, he again tested positive for SARS-CoV-2 on PCR. This viral strain also had whole genome sequencing.
Interestingly, they were two different viral strains supporting the notion that this individual had been re-infected by a different SARS-CoV-2 strain 4.5 months after he initially contracted COVID-19! Check out the video for all the details and more!
Oh wells
Back to trips,, ...that made me laugh!!!
$RLFTF Absolutely
RE: Look at the clinical Data, it's stellar and should be your guiding star in all this nonsense information. It's all that counts in the end with this stock. No other company has a drug even close to this one. I'm more than just convinced about this drug!
Covid-19 vaccines: Experts call for independent commission separate from FDA to review data http://a.msn.com/01/en-us/BB18x1so?ocid=st
$RLFTF How would I treat myself if I got COVID-19?
August 30, 2020
Gabe Mirkin
Dr. Gabe Mirkin
I have received many emails asking me how I would treat myself if I developed COVID-19.
If I had COVID-19 and was not very sick, I do not know if I would take anything.
Today there are no drugs or treatments proven to prevent or cure COVID-19, and the U.S. Food and Drug Administration (FDA) has not licensed any treatment specifically for the virus, but has allowed emergency use for some treatments.
Since a successful drug will bring billions of dollars to the company that develops it, you have to be very cautious about many of the press releases put out by companies racing to find treatments.
If I had only mild symptoms, I would probably just take it easy (as I would with the flu or a bad cold) and not take any drugs. However, new controlled studies are being reported daily so my opinion may change at any time. People with heart disease, lung disease, diabetes, auto-immune disease, cancer or obesity and those over 65 are at increased risk for complications, so their doctors may elect to prescribe some of the treatments listed below. (cont'd)
https://www.villages-news.com/2020/08/30/how-would-i-treat-myself-if-i-got-covid-19/
Update: 8/30 PM
No x-rays today. Vent in APRV mode and set currently at 70%. ECMO is still at 100%. All other labs and vitals looking great! No additional blood was needed today.
One shot of coronavirus vaccine likely won't be enough http://a.msn.com/05/en-us/BB18wDYO?ocid=st
One shot of coronavirus vaccine likely won't be enough http://a.msn.com/05/en-us/BB18wDYO?ocid=st
A lot of us here own both.. I'm not interested in sharing my email they ask for to sign it, I am not desperate.. but this is off topic for this board and some of the energy behind the replies here are creepy. "Putting out another's candle doesn't make your light shine brighter"
$RLFTF Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
?Jonathan Javitt * and ?Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
How to cite: Javitt, J.; Youssef, J. Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide.
Preprints 2020, 2020080640 (doi: 10.20944/preprints202008.0640.v1).
Javitt, J.; Youssef, J. Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide.
Preprints 2020, 2020080640 (doi: 10.20944/preprints202008.0640.v1).
Abstract
Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect the Alveolar Type II cell by blocking replication of the SARS-CoV-2 virus, upregulating surfactant production, blocking apoptosis, and blocking cytokine effects.
RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation and is currently in phase 2/3 placebo-controlled trials.
FDA has granted Emergency Use IND and Expanded Access Protocol approval for the use of RLF-100 in patients whose comorbidities render them ineligible for inclusion in the ongoing pivotal trial.
Methods: This report describes the first 6 patients with Acute Respiratory Failure in Critical COVID-19, enrolled under Emergency Use IND were treated with three successive 12-hour infusions of intravenous Aviptadil at 50/100/150 pmol/kg/hr, while continuing to receive maximal ICU care.
Results: Median patient follow-up time is 14 days. So far, all treated patients have survived.
Improved radiographic appearance of typical “ground glass” COVID-19 features to varying degrees is seen in all patients within 72 hours.
Improvement in blood oxygenation is seen in all patients, with complete remission from respiratory failure in 4 of 6 patients. An average 56% reduction in inflammatory markers was seen, together with a median 4 point reduction in the NIAID Ordinal Scale. 2/6 patients were discharged from the hospital and 1 patient was downgraded to the general medicine floor.
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent.
Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect
$RLFTF Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
?Jonathan Javitt * and ?Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
How to cite: Javitt, J.; Youssef, J. Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide.
Preprints 2020, 2020080640 (doi: 10.20944/preprints202008.0640.v1).
Javitt, J.; Youssef, J. Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide.
Preprints 2020, 2020080640 (doi: 10.20944/preprints202008.0640.v1).
Abstract
Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect the Alveolar Type II cell by blocking replication of the SARS-CoV-2 virus, upregulating surfactant production, blocking apoptosis, and blocking cytokine effects.
RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation and is currently in phase 2/3 placebo-controlled trials.
FDA has granted Emergency Use IND and Expanded Access Protocol approval for the use of RLF-100 in patients whose comorbidities render them ineligible for inclusion in the ongoing pivotal trial.
Methods: This report describes the first 6 patients with Acute Respiratory Failure in Critical COVID-19, enrolled under Emergency Use IND were treated with three successive 12-hour infusions of intravenous Aviptadil at 50/100/150 pmol/kg/hr, while continuing to receive maximal ICU care.
Results: Median patient follow-up time is 14 days. So far, all treated patients have survived.
Improved radiographic appearance of typical “ground glass” COVID-19 features to varying degrees is seen in all patients within 72 hours.
Improvement in blood oxygenation is seen in all patients, with complete remission from respiratory failure in 4 of 6 patients. An average 56% reduction in inflammatory markers was seen, together with a median 4 point reduction in the NIAID Ordinal Scale. 2/6 patients were discharged from the hospital and 1 patient was downgraded to the general medicine floor.
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent.
Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect
$RLFTF NeuroRx’s RLF-100: the key to treating and preventing Covid-19 respiratory failure? https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/ via @PharmaTechFocus
Results will be louder than any of the issues being brought here up from time to time IMO - RESULTS -
DIABETIC PERIPHERAL NEUROPATHY TREATMENT MARKET 2020 IN-DEPTH ANALYSIS OF INDUSTRY SHARE, SIZE, GROWTH OUTLOOK UP TO 2025
Companies which formulate the competitive arena of the Diabetic Peripheral Neuropathy Treatment market are The major players covered in Diabetic Peripheral Neuropathy Treatment are:, Achelios Therapeutics Inc, Mitsubishi Tanabe Pharma Corp, Grunenthal GmbH, Celgene Corp, Medifron DBT Co Ltd, Commence Bio Inc, Reata Pharmaceuticals Inc, KPI Therapeutics Inc, Immune Pharmaceuticals Inc, Novaremed Ltd, (( Relief Therapeutics Holding AG )) and ViroMed Co Ltd.
https://bulletinline.com/2020/08/28/diabetic-peripheral-neuropathy-treatment-market-2020-in-depth-analysis-of-industry-share-size-growth-outlook-up-to-2025/